Fulcrum Therapeutics, Inc is a biotechnology business based in the US. Fulcrum Therapeutics shares (FULC) are listed on the NASDAQ and all prices are listed in US Dollars. Fulcrum Therapeutics employs 73 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Fulcrum Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – FULC – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Fulcrum Therapeutics stock price (NASDAQ: FULC)Use our graph to track the performance of FULC stocks over time.
Fulcrum Therapeutics shares at a glance
|Latest market close||$8.93|
|52-week range||$7.01 - $18.38|
|50-day moving average||$9.26|
|200-day moving average||$11.07|
|Wall St. target price||$20.88|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-50.40|
Buy Fulcrum Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Fulcrum Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Fulcrum Therapeutics price performance over time
|1 week (2021-07-18)||N/A|
|1 month (2021-06-29)||-6.10%|
|3 months (2021-04-29)||-20.48%|
|6 months (2021-01-25)||N/A|
|1 year (2020-07-25)||N/A|
|2 years (2019-07-25)||N/A|
|3 years (2018-07-25)||N/A|
|5 years (2016-07-25)||N/A|
Fulcrum Therapeutics financials
|Revenue TTM||$12.9 million|
|Gross profit TTM||$-46,839,000|
|Return on assets TTM||-34.74%|
|Return on equity TTM||-69.93%|
|Market capitalisation||$275.8 million|
TTM: trailing 12 months
Shorting Fulcrum Therapeutics shares
There are currently 854,988 Fulcrum Therapeutics shares held short by investors – that's known as Fulcrum Therapeutics's "short interest". This figure is 29.1% up from 662,496 last month.
There are a few different ways that this level of interest in shorting Fulcrum Therapeutics shares can be evaluated.
Fulcrum Therapeutics's "short interest ratio" (SIR)
Fulcrum Therapeutics's "short interest ratio" (SIR) is the quantity of Fulcrum Therapeutics shares currently shorted divided by the average quantity of Fulcrum Therapeutics shares traded daily (recently around 260667.07317073). Fulcrum Therapeutics's SIR currently stands at 3.28. In other words for every 100,000 Fulcrum Therapeutics shares traded daily on the market, roughly 3280 shares are currently held short.
However Fulcrum Therapeutics's short interest can also be evaluated against the total number of Fulcrum Therapeutics shares, or, against the total number of tradable Fulcrum Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fulcrum Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Fulcrum Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0464% of the tradable shares (for every 100,000 tradable Fulcrum Therapeutics shares, roughly 46 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Fulcrum Therapeutics.
Find out more about how you can short Fulcrum Therapeutics stock.
Fulcrum Therapeutics share dividends
We're not expecting Fulcrum Therapeutics to pay a dividend over the next 12 months.
Fulcrum Therapeutics share price volatility
Over the last 12 months, Fulcrum Therapeutics's shares have ranged in value from as little as $7.01 up to $18.375. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fulcrum Therapeutics's is 0.9076. This would suggest that Fulcrum Therapeutics's shares are less volatile than average (for this exchange).
Fulcrum Therapeutics overview
Fulcrum Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc.
Stocks similar to Fulcrum Therapeutics
Fulcrum Therapeutics in the news
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
new option listings and one option delisting on July 14th
Fulcrum Therapeutics management to meet virtually with Piper Sandler
Frequently asked questionsWhat percentage of Fulcrum Therapeutics is owned by insiders or institutions?
Currently 8.076% of Fulcrum Therapeutics shares are held by insiders and 80.96% by institutions. How many people work for Fulcrum Therapeutics?
Latest data suggests 73 work at Fulcrum Therapeutics. When does the fiscal year end for Fulcrum Therapeutics?
Fulcrum Therapeutics's fiscal year ends in December. Where is Fulcrum Therapeutics based?
Fulcrum Therapeutics's address is: 26 Landsdowne Street, Cambridge, MA, United States, 02139 What is Fulcrum Therapeutics's ISIN number?
Fulcrum Therapeutics's international securities identification number is: US3596161097 What is Fulcrum Therapeutics's CUSIP number?
Fulcrum Therapeutics's Committee on Uniform Securities Identification Procedures number is: 359616109
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert